1 Reason Dendreon Continues to March Higher


Dendreon is posting another day of impressive gains, and with today's high-single-digit move, the stock has gained about 75% from its early November lows. That's not to say things are looking great for the company -- all it takes is a glance at the stock price from early 2011 to remember just how far the maker of prostate cancer treatment Provenge has fallen. But as Brenton Flynn outlines in the video below, there's likely one simple explanation for the outsized gains we've seen over the past 90 days.

Interested in the full story behind Dendreon? Be sure to check out our brand new premium research report on this roller coaster stock. Inside, our Denderon expert David Williamson details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

The article 1 Reason Dendreon Continues to March Higher originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Bank of America, Dendreon, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.